Φορτώνει......
Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications
BACKGROUND: Entrectinib is a tropomyosin receptor kinase inhibitor approved for the treatment of neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours based on single-arm trials. Traditional randomised clinical trials in rare cancers are not feasible; we conducted an intrapatien...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | ESMO Open |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Elsevier
2021
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8103537/ https://ncbi.nlm.nih.gov/pubmed/33676294 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.esmoop.2021.100072 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|